ArticleEmerging infectious diseases2024
Clinical Significance, Species Distribution, and Temporal Trends of Nontuberculous Mycobacteria, Denmark, 1991-2022.
Article in Emerging infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Non-tuberculous mycobacterial infections in mainland China and Taiwan: a systematic review and meta-analysis of epidemiology, species distribution, and drug resistance (2013-2024).Frontiers in public health · 2025Pooled it
- Macrolide-resistantJournal of clinical tuberculosis and other mycobacterial diseases · 2026Review
- Current Perspectives onInternational journal of molecular sciences · 2026Review
- Seven decades of nontuberculous mycobacteria in Denmark: shifts in species distribution and clinical relevance.Journal of clinical microbiology · 2026Article
- Zoonotic Nontuberculous Mycobacteria: Transmission Pathways, Laboratory Diagnosis, Detection Methodologies, and One Health Priorities.Infectious diseases & clinical microbiology · 2026Review
- Inhaled Corticosteroids and Non-Tuberculous Mycobacteria Risk in Patients with COPD.Journal of clinical medicine · 2026Article
- Nontuberculous mycobacterial pulmonary disease: a nationwide cost analysis of healthcare costs, foregone earnings and public benefits in a universal healthcare setting.ERJ open research · 2026Article
- Molecular epidemiology of non-tuberculous mycobacteria in clinical samples from Jiangxi Province, 2021-2023.BMC microbiology · 2026Article
- Treatment and outcomes in patients with non-TB mycobacterial pulmonary disease: a single-centre study.IJTLD open · 2026Article
- Mortality and Causes of Death in Patients WithOpen forum infectious diseases · 2025Article
- Species distribution of nontuberculous mycobacteria isolated from respiratory specimens at a tertiary care hospital in South Korea, 2017-2022.Microbiology spectrum · 2025Article
- The gut-lung axis and microbiome dysbiosis in non-tuberculous mycobacterial infections: immune mechanisms, clinical implications, and therapeutic frontiers.Gut pathogens · 2025Review
- Relationship between age, sex, geography and incidence of nontuberculous mycobacteria in Denmark from 1991 to 2022.ERJ open research · 2025Article
- A Year in Review on Tuberculosis and Non-tuberculous Mycobacteria Disease: A 2025 Update for Clinicians and Scientists.Pathogens & immunity · 2025Review
- Facial cutaneous tuberculosis infected by non-tuberculous mycobacteria.BMC infectious diseases · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nontuberculous mycobacteria (NTM) are emerging as notable causative agents of opportunistic infections. To examine clinical significance, species distribution, and temporal trends of NTM in Denmark, we performed a nationwide register-based study of all unique persons with NTM isolated in the country during 1991-2022. We categorized patients as having definite disease, possible disease, or isolation by using a previously validated method. The incidence of pulmonary NTM increased throughout the study period, in contrast to earlier findings. Mycobacterium malmoense, M. kansasii, M. szulgai, and M. avium complex were the most clinically significant species based on microbiologic findings; M. avium dominated in incidence. This study shows the need for surveillance for an emerging infection that is not notifiable in most countries, provides evidence to support clinical decision-making, and highlights the importance of not considering NTM as a single entity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.